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ABSTRACT
Objectives: This study aims to determine the prevalence of vitamin D deficiency in Pakistani systemic lupus erythematosus (SLE) patients and the 
effect of vitamin D deficiency on the severity and outcomes of SLE.
Patients and methods: This retrospective study evaluated SLE patients presenting to our hospital between January 2009 and December 2018. 
A total of 98 patients (13 males, 85 females; mean age 39.8±14.9 years; range, 16 to 73 years) with vitamin D levels available at the time of diagnosis 
were included in the study. Disease activity was measured using SLE disease activity score at the time of diagnosis and at the two-year mark.
Results: Sixty-five patients were deficient in Vitamin D and out of those 46 were severely deficient. The severe disease group had more patients with 
vitamin D deficiency at both visits (43/78 and 33/46) while patients in remission all had normal vitamin D (12/12 and 14/14) (p≤0.001).
Conclusion: Vitamin D deficiency is common in SLE patients and also significantly associated with increased disease activity at the time of diagnosis 
and at the two-year mark. We hope this study becomes a platform for the global medical community to come together and implement early 
screening and monitoring of vitamin D levels and to determine the optimal level of supplementation for prevention of poor outcomes in SLE.
Keywords: Autoimmune disease, rheumatology, systemic lupus erythematosus, vitamin D.
Vitamin D is the common denomination 
of a collection of sterols belonging to a 
class of secosteroids playing a vital role in 
phosphocalcic metabolism. The main circulating 
form of vitamin D is 25-hydroxy vitamin D 
(25-(OH)D) formed by hydroxylation of 
cholecalciferol in the liver.1,2 Its function is 
mediated through the vitamin D receptors (VDRs) 
which are not only found in bones and kidney 
but also in muscles.1 Immune cells including 
the dendritic cells, macrophages, monocytes, 
and lymphocytes (B and T cells) are capable 
of converting 25-(OH)D3 to 1,25-(OH)2D3, 
theoretically endowing the immunocytes with a 
higher level of vitamin D-related immune response 
control at the inflamed sites and demonstrating 
the important role that vitamin D has in the 
immune system.2 Another piece of evidence 
that suggests a potential role of vitamin D in the 
immune system and the mediation of autoimmune 
diseases is the presence of VDR polymorphisms, 
namely, ApaI, FokI, BsmI, and TaqI, which have 
been found to be associated with the development 
of autoimmunity.2,3
Systemic lupus erythematosus (SLE) is a 
multisystem autoimmune inflammatory disease 
mainly affecting females of childbearing age. It 
is characterized by a large spectrum of clinical 
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manifestations accompanied by prototypic 
abnormalities of the immune system characterized 
by immune-complex induced inflammation.4
One of the most effective ways of assessing 
severity of this disease is by continuously 
monitoring disease activity which also helps 
in determining prognosis and extent of organ 
damage, ultimately dictating the treatment 
modality. The SLE Disease Activity Index 2000 
(SLEDAI-2K) has been the most widely used 
SLE disease activity measure.5 However, the 
performance of SLEDAI in detecting clinically 
meaningful changes in disease activity is 
limited, since each item of SLEDAI is scored 
dichotomically, with the same numerical weight 
regardless of the severity of change observed.6 In 
addition, potentially severe lupus manifestations, 
such as hemolytic anemia, pneumonitis, types 
of rash, and systemic vasculitis are not scored in 
SLEDAI.6
These limitations had important implications 
on target-driven management of SLE in daily 
clinical practice, and in assessing the efficacy of 
new medications in clinical trials. Thus, there was 
an urgent need for a new tool which was able to 
accurately capture clinically meaningful changes 
in SLE disease activity. Jesus et al.,6 validated 
a new tool for the measurement of SLE disease 
activity: the SLE disease activity score (SLE-DAS). 
This provides an accurate, continuous, and user-
friendly global measure of SLE disease activity 
with improved sensitivity to change and high 
specificity, in comparison to SLEDAI-2K.
Systemic lupus erythematosus patients are at 
a heightened risk of being deficient in vitamin D 
due to reduced exposure to the sun, renal damage, 
and continuous use of medications (such as 
chronic steroids and hydroxychloroquine) with 
the potential of altering metabolism of vitamin D.7 
SLE has been found to be substantially T-cell 
driven with the T helper type 1 (Th1) and Th17 
cluster of differentiation 4+ T cells being chiefly 
responsible for driving the pro-inflammatory 
response in SLE.8 As 1,25-(OH)2D3 dampens 
the pro-inflammatory response of Th17, it is 
theoretically possible to suppress the SLE disease 
with vitamin D treatment.
Studies from around the world have stated 
the prevalence of vitamin D deficiency in SLE 
patients to be varied but up to 90% in some 
articles.1,9 Unfortunately, there is scarcity of local 
data to look for vitamin D status in autoimmune 
diseases. Only two articles were found that show 
the relationship of vitamin D with rheumatoid 
arthritis and vitiligo in Pakistani population;10,11 
however, to our knowledge, no study has been 
conducted investigating the association of SLE and 
vitamin D in Pakistani population. Therefore, in 
this study, we aimed to determine the prevalence 
of vitamin D deficiency in Pakistani SLE patients 
and the effect of vitamin D deficiency on the 
severity and outcomes of SLE.
PATIENTS AND METHODS
This retrospective study was conducted at 
Department of Medicine, Aga Khan University 
Hospital. A total of 500 patients were diagnosed 
as SLE during hospital stay or clinic appointment 
between January 2009 and December 2018. 
Diagnosis of SLE was confirmed by applying 
the Systemic Lupus International Collaborating 
Clinics-12 criteria.12 This visit was characterized 
as the first visit (even if the patient had disease 
previously or had been newly diagnosed) to 
the hospital and vitamin D levels were noted 
from this visit. The second visit of the patient 
was taken after 48 months and disease activity 
was assessed at both visits and then compared 
with relation to vitamin D level. Patients with 
vitamin D not checked within one week of the 
first visit or those who were already on vitamin D 
supplements, or had other existing connective 
tissue diseases, hepatitis B, hepatitis C, 
human immunodeficiency virus, sarcoidosis, 
parathyroid disorders, chronic liver disease, or 
chronic kidney disease were excluded. Finally, 
98 patients (13 males, 85 females; mean age: 
39.8±14.9 years; range, 16 to 73 years) were 
included. The study protocol was approved by 
the Ethical Review Committee of the Aga Khan 
University Hospital. A written informed consent 
was obtained from each patient. The study was 
conducted in accordance with the principles of 
the Declaration of Helsinki.
The data were collected from the medical 
records of patients using a pre-designed pro forma. 
Information collected included demographics, 
clinical characteristics of SLE, vitamin D levels, 
and SLE-DAS at the time of diagnosis and at 
the two-year mark. Disease activity was also 
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monitored via complement component (C) 3, 
C4, and anti-double-stranded deoxyribonucleic 
acid (anti-dsDNA). Anti-dsDNA was labeled as 
positive with values of greater than 25 IU/mL 
while C3 and C4 values of less than 0.8 and 
0.1 were considered as significant. Vitamin D 
levels were categorized as normal (more than 
20 ng/mL), mild deficiency (less than 20 ng/mL), 
and severe deficiency (less than 12 ng/mL). 
SLE-DAS was used to calculate DAS at both visits 
and then on the basis of the score, the disease 
was appropriately categorized as remission (less 
than 2.08), low disease activity (less than 3.77), 
moderate disease activity (less than 7.64), and 
severe disease activity (more than 7.64).6
Statistical analysis
The IBM SPSS version 22.0 software (IBM 
Corp., Armonk, NY, USA) was used for statistical 
analysis. Qualitative variables were presented 
as frequency and percentages and continuous 
variables as mean with standard deviation. For 
continuous variables, we used Student t-test 
or Wilcoxon rank-sum test and chi-square test 
or Fisher exact test for categorical variables 
to identify differences between the vitamin D 
deficient and non-deficient groups. P value 
less than 0.05 was considered statistically 
significant.
RESULTS
Among the included patients, 87% 
were females and the mean age at the 
time of diagnosis was 39.8±14.9 years 
(range, 16 to 73 years). The most common 
clinical manifestations were mucosal ulcers 
Table 1. Comparison of demographics and clinical characteristics of systemic lupus erythematosus patients according 
to level of vitamin D deficiency
Level of vitamin D deficiency
Overall
(n=98)
Normal vitamin D 
level (n=33)









































Arthritis 51 15 12 24 0.469
Localized rash 44 14 11 19 0.445
Generalized rash 24 8 3 13 0.568
Alopecia 21 7 1 13 0.121
Mucosal ulcers 56 16 10 30 0.302
Systemic vasculitis 25 6 6 13 0.476
Mucocutaneous vasculitis 21 8 2 11 0.435
Neuropsychiatric symptoms 12 1 1 10 0.026
Serositis 20 4 1 15 0.016
Cardiopulmonary features 23 3 3 17 0.011
Myositis 19 2 2 15 0.007
Proteinuria 29 9 2 18 0.067
Leukopenia 15 3 5 7 0.252
Hemolytic anemia 31 4 5 22 0.001
Thrombocytopenia 31 3 6 22 0.003
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(n=56; 57%), arthritis (n=51; 52%), and 
localized rash (n=44; 452%). Mean vitamin 
D level was 19.9±17.8 (range, 1.5 to 85.9). 
Sixty-five patients were deficient in Vitamin D 
and out of those 46 were severely deficient. 
Table 1 compares the clinical characteristics 
of SLE with vitamin D level status. Severe 
vitamin D deficiency was significantly associated 
with neuropsychiatric symptoms, serositis, 
cardiopulmonary features, myositis, hemolytic 
anemia, and thrombocytopenia (p≤0.05).
The overall mean SLE-DASs at diagnosis 
and at the two-year mark were 30.9±19.0 
(range, 0 to 80) and 10.9±10.4 (range, 0 to 54), 
respectively. Figure 1 illustrates the inverse 
relationship between the vitamin D levels and 
the SLE-DASs. Table 2 shows the comparison 
between vitamin D levels and SLE disease 
activity indicators. C3 and C4 levels showed 
a significant association with vitamin D levels 
(p≤0.05). Furthermore, there was a significant 
association between SLE-DAS status and vitamin 
D deficiency. The severe disease group had more 
patients with vitamin D deficiency at both visits 
(43/78 and 33/46) while patients in remission 
all had normal vitamin D (12/12 and 14/14) 
(p≤0.001).
DISCUSSION
The role of vitamin D and the impact of its 
deficiency on multiple autoimmune diseases have 
long been a subject of discussion in the medical 
literature. SLE patients have a complicated 
relationship with vitamin D. The reason behind 
this is because some researchers believe that 
Table 2. Comparison of systemic lupus erythematosus disease activity indicators according to level of vitamin D 
deficiency
Level of vitamin D deficiency
Overall
(n=98)
Normal vitamin D 
level (n=33)
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ANA 62 17 12 33 0.184
Anti-dsDNA 68 19 14 35 0.192













































ANA: Antinuclear antibody; Anti-dsDNA: Anti-double-stranded deoxyribonucleic acid antibody; C3 and C4: Complement components 3 and 4; SLE-DAS: Systemic lupus 
erythematosus-disease activity score.
Figure 1. Scatter plot showing inverse relationship 
between vitamin D levels and systemic lupus erythematosus 
disease activity scores at end of study period (48 months 
after first visit). 
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SLE patients have multiple risk factors resulting 
in vitamin D deficiency, while the rest are of the 
opinion that vitamin D deficiency is itself a cause 
of SLE in such patients.9
The results of this study have demonstrated 
that vitamin D deficiency is an extremely common 
occurrence in SLE patients with two thirds being 
deficient and more than half being severely 
deficient. It has also showed that there is a strong 
association between vitamin D deficiency and 
disease activity. Other studies have displayed a 
similar level of prevalence which ranges from 
16 to 96% and can vary depending on a number 
of factors such as environmental, geographical, 
and genetic factors.13
The mean vitamin D level in the present study 
was 19.8±17.8 ng/mL, which is almost similar to 
that seen in Egypt (17.6±6.9 ng/mL), Saudi Arabia 
(19.1±9.5 ng/mL), and Spain (22 ng/mL).1,9,14 In 
contrast, an Indian study reported very low mean 
vitamin D level of around 11.61.15 However, 
prevalence of vitamin D deficiency in the present 
study was around 64.3% which is quite lower 
than all four studies above which have mentioned 
a prevalence of greater than 90% in each. As 
this is a retrospective study, this might be due to 
the poor data record.
There are few studies evaluating the association 
of vitamin D deficiency and SLE disease activity 
and even fewer assessing long-term outcomes. 
Our study demonstrates an inverse relationship 
between vitamin D levels and SLE disease 
activity. Patients with vitamin D deficiency had 
a significantly higher disease activity at the 
time of diagnosis and two years later. A recent 
report by Amital et al.16 displayed similar results 
using the SLEDAI and European Consensus 
Lupus Activity Measurement scoring systems, and 
presented an inverse correlation between the two 
variables. Similarly, Ben-Zvi et al.17 also reported 
an increasing trend of disease activity with 
decreasing vitamin D levels. Dutta et al.,18 in their 
very recent study from India, concluded that the 
vitamin D deficient group was three times more 
likely of developing high disease activity (odds 
ratio: 3.9; p<0.05) compared with the control 
group.
This study has some limitations. The findings 
of the study are limited due to a retrospective 
study design, small sample size because of fewer 
patients having recorded Vitamin D levels and due 
to the use of a new scale for assessing disease 
severity which has not been used at a big scale. 
Furthermore, since the majority of the patients 
presenting to our tertiary hospital had either 
been previously admitted elsewhere or were from 
far-flung areas, true vitamin D values could not be 
found. Another problem with retrospective data 
collection was the quality of the data in the file 
and the variability in the examinations performed 
by physicians. Still, this study is the first of its 
kind from Pakistan which assesses the prevalence 
of vitamin D deficiency in SLE patients and also 
demonstrates the association between vitamin D 
deficiency and SLE disease activity. It offers new 
local information to clinicians which can influence 
clinical practice. However, to better understand 
the impact of vitamin D deficiency on SLE 
patients and to assess its prognostic significance, 
further specifically designed prospective cohort 
studies are needed.
In conclusion, vitamin D deficiency is 
prevalent in SLE patients and is significantly 
associated with more active disease at the time 
of diagnosis and at the two-year mark. We 
hope this study becomes a platform for the 
global medical community to come together and 
implement early screening and monitoring of 
vitamin D levels and to determine the optimal 
level of supplementation for prevention of poor 
outcomes in SLE.
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